Prodrugs of a CDK inhibitor for treating cancers
US11725020B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 13, 2021 |
| Grant date | Aug 15, 2023 |
| Priority date | — |
| Expiry date | Dec 13, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.